Donald Beahm, MD
Otolaryngology · Philadelphia, PANPI 1245423714
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $3,340 with a category attached, or 74.9%. Medtronic accounts for 76.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $2,570 and has fallen 91.8% since, to $211 in 2025.
Across 14 payments — averaging $238.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Acclarent, Inc$337
- Stryker$157
- Intersect ENT, Inc.$131
- Aerin Medical Inc.$130
- Integra Lifesciences Corporation$27
- plus $14 from 1 others
Across 18 payments — averaging $3824.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$69K
What the payments were for
- Speaking & faculty fees$2,50075%
- Food & beverage$84025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $2,544 |
| Acclarent, Inc | 2 | $337 |
| Stryker | 5 | $157 |
| Intersect ENT, Inc. | 1 | $131 |
| Aerin Medical Inc. | 2 | $130 |
| Integra Lifesciences Corporation | 1 | $27 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROPEL$2,631
- Acclarent Navwire$267
- VIVAER STYLUS$116
- RHINAER STYLUS$116
How this compares
$3,340 in reported general payments places this provider in the 75th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $44,861 |
| Budesonide | 15 | $7,036 |
| Dexamethasone Sodium Phosphate | 23 | $4,391 |
| Mometasone Furoate | 53 | $4,119 |
| Ipratropium Bromide | 30 | $1,581 |
| Azelastine Hcl | 38 | $1,159 |
| Prednisolone Acetate | 11 | $548 |
| Mupirocin | 66 | $529 |
| Doxycycline Hyclate | 36 | $496 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 37 | $432 |
| Cefdinir | 12 | $333 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 32 | $228 |
| Prednisone | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Philadelphia
- Nancy SnydermanPhiladelphia$4.5M
- David KennedyPhiladelphia$603K
- James PalmerPhiladelphia$331K
- Mathew NagorskyPhiladelphia$95K
- Noam CohenPhiladelphia$76K
- Nithin AdappaPhiladelphia$72K
- Steven CannadyPhiladelphia$33K
- David CognettiPhiladelphia$30K
- John KrousePhiladelphia$30K
- Soo AbboudPhiladelphia$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.